Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.97 |
| ▸ | HTR2C | P28335 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desipramine SCHEMBL5501781 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29364790 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL2944786 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL5072939 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL34384 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29379525 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29085912 | 0.97 | SLC6A4 (0.97) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL41993 | 0.95 | SLC6A4 (0.94) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL27517227 | 0.90 | SLC6A4 (0.83) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL28105338 | 0.90 | SLC6A4 (0.83) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5663 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025087695-A1 | METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES | ASCEND ADVANCED THERAPIES LTD (GB) | 2025-05-01 | — | — | WO | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |